Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants

Brazil currently has a 10-valent pneumococcal conjugate vaccine (PCV10) pediatric national immunization program (NIP). However, in recent years, there has been significant progressive increases in pneumococcal disease attributed to serotypes 3, 6A, and 19A, which are covered by the 13-valent PCV (PC...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Hum Vaccin Immunother
Auteurs principaux: Perdrizet, Johnna, Santana, Carlos Felipe S., Senna, Thais, Alexandre, Rodrigo Fernandes, Sini de Almeida, Rodrigo, Spinardi, Julia, Wasserman, Matt
Format: Artigo
Langue:Inglês
Publié: Taylor & Francis 2020
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8018448/
https://ncbi.nlm.nih.gov/pubmed/32966176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2020.1809266
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires